Liz Elmhirst
Corporate Officer/Principal presso Achilles Therapeutics UK Ltd.
Provenienza dei contatti di primo grado di Liz Elmhirst
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom.
10
| Public Company | Biotechnology | 10 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Liz Elmhirst tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal | |
ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO | |
3I GROUP PLC | Investment Managers | Corporate Officer/Principal | |
RA Capital Management LP
RA Capital Management LP Investment ManagersFinance RA Capital Management LP (RA Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Peter Kolchinsky in 2004. RA Capital provides discretionary investment advisory services to Healthcare Funds and the Nexus Funds which are open only to certain financially sophisticated and high net-worth individuals and entities. | Investment Managers | Analyst-Equity | |
SYNCONA LIMITED | Investment Trusts/Mutual Funds | Chief Executive Officer Corporate Officer/Principal | |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | College/University | Doctorate Degree | |
College of the Holy Cross (Massachusetts) | College/University | Undergraduate Degree | |
University of Cambridge | College/University | Doctorate Degree Doctorate Degree Graduate Degree | |
The Johns Hopkins University | College/University | Undergraduate Degree | |
Oxxon Therapeutics, Inc.
Oxxon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oxxon Therapeutics, Inc. develops and manufactures antigen-specific immunotherapies to treat patients with chronic infectious diseases and cancer. The company has three development programs in hepatitis, melanoma, and HIV. Oxxon Therapeutics was founded in 1999 by Dr. Joerg Schneider and is located at Oxford, UK. | Pharmaceuticals: Major | Director/Board Member | |
National Institutes of Health
National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | General Government | Corporate Officer/Principal | |
London Business School | College/University | Undergraduate Degree | |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor | |
The Royal Society of Medicine
The Royal Society of Medicine Miscellaneous Commercial ServicesCommercial Services The Royal Society of Medicine provides postgraduate medical education. The Society provides a range of educational activities and opportunities for doctors, dentists and veterinary surgeons, including students, and for allied healthcare professionals. It also promotes an exchange of information and ideas on the science, practice and organization of medicine, both within the health professions and with responsible and informed public opinion. The Society was founded in 1805 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
EPIZYME, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
McKinsey & Co., Inc. (United Kingdom)
McKinsey & Co., Inc. (United Kingdom) Investment ManagersFinance Part of McKinsey & Co., Inc., McKinsey & Co., Inc. (United Kingdom) is a consulting firm that helps UK manufacturers embrace new technologies for digital transformation and leadership. The company is based in London, UK. Ruben Schaubroeck, McKinsey Digital's new lead for the UK, Belgium, and Netherlands offices, spoke with Thomas Farrar, a manager of communications in the firm's UK office, about the importance of speed and pace for CEOs in this new growth journey. The British company works with organizations that pursue sustainability, inclusion, and economic growth, all at the same time, to achieve strategic foresight and built-in agility in the face of the COVID-19 pandemic and the new trading relationship with the EU. | Investment Managers | Corporate Officer/Principal | |
Xention Ltd.
Xention Ltd. Pharmaceuticals: MajorHealth Technology Part of Xention Pharma Ltd., Xention Ltd. is a British company that develops and researches drugs. The company is based in Newmarket, UK. Xention was founded in 2002. | Pharmaceuticals: Major | Director/Board Member | |
UCL Cancer Institute Research Trust | Corporate Officer/Principal | ||
University College London Hospitals NHS Foundation Trust
University College London Hospitals NHS Foundation Trust Hospital/Nursing ManagementHealth Services University College London Hospitals NHS Foundation Trust provides first-class acute and specialist services in six hospitals in central London, UK. The British company's mission is to deliver top-quality patient care, excellent education, and world-class research. The company also offers events, classes, and workshops at the Macmillan Support and Information Service (MSIS) and an audiological service for GPs who would like to refer patients for age-related audiological assessments. Additionally, the company provides information about the sarcoma service and hearing therapists who work with adults who have hearing loss and associated disorders, such as tinnitus and hyperacusis, and other forms of hypersensitivity. The company is ultimately controlled by the Government of United Kingdom. | Hospital/Nursing Management | Corporate Officer/Principal | |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Investment Managers | Chief Executive Officer Private Equity Investor Private Equity Investor | |
Oxford University Medical School | College/University | Undergraduate Degree | |
Autolus Ltd.
Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | Biotechnology | Chairman | |
RAPT THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Blue Earth Diagnostics Ltd.
Blue Earth Diagnostics Ltd. Medical/Nursing ServicesHealth Services Blue Earth Diagnostics Ltd. engages in the development and commercialization of positron emission tomography imaging agents. It focuses on the molecular imaging diagnostics. The company was founded in March 2014 and is headquartered in Oxford, the United Kingdom. | Medical/Nursing Services | Chairman Director/Board Member Director/Board Member | |
Syncona LLP
Syncona LLP Financial ConglomeratesFinance Syncona LLP operates as a healthcare investment company. It invests in companies which focus on gene therapy, cell therapy and patient stratification technologies. The company was founded on October 19, 2012 and is headquartered in London, the United Kingdom. | Financial Conglomerates | Chief Executive Officer | |
Syncona Investment Management Ltd.
Syncona Investment Management Ltd. Investment ManagersFinance Syncona Investment Management Ltd. (Syncona) is the asset management subsidiary of Syncona Ltd. in Great Britain. Headquartered in London, the firm was co-founded by Martin Murphy alongside The Wellcome Trust. Syncona is focused on founding, building and funding a portfolio of global leaders in life science. | Investment Managers | Chairman | |
AUTOLUS THERAPEUTICS PLC | Biotechnology | Director/Board Member | |
Azeria Therapeutics Ltd.
Azeria Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Azeria Therapeutics Ltd. engages in the research and development of pharmaceutical products. It develops treatments for hormone resistance that targets breast and prostate cancer patients. The company was founded by Jason Carroll in 2017 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Chairman | |
89BIO, INC. | Pharmaceuticals: Major | Director/Board Member | |
Anaveon AG
Anaveon AG BiotechnologyHealth Technology Anaveon AG engages in the development of immune therapies against cancer. Its compounds promote effector T-cell functions to enhance a patient?s immune system to respond to tumors. The company was founded on December 11, 2017 by Onur Boyman and Andreas Katopodis and is headquartered in Bottmingen, Switzerland. | Biotechnology | Chairman | |
89Bio Ltd.
89Bio Ltd. Pharmaceuticals: MajorHealth Technology Part of 89bio, Inc., 89Bio Ltd. is an Israeli company that develops therapies and drugs for the treatment of patients living with nonalcoholic steatohepatitis. The company is based in Herzliya, Israel. | Pharmaceuticals: Major | Director/Board Member | |
WEREWOLF THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Quell Therapeutics Ltd.
Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
ACHILLES THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member Director/Board Member Chief Executive Officer Founder Director/Board Member | |
Neogene Therapeutics, Inc.
Neogene Therapeutics, Inc. BiotechnologyHealth Technology Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY. | Biotechnology | Director/Board Member Director/Board Member | |
Clade Therapeutics, Inc.
Clade Therapeutics, Inc. BiotechnologyHealth Technology Clade Therapeutics, Inc. is a company that aims to discover and deliver next-generation cell medicines to improve the lives of patients in need. Clade Therapeutics is based in Boston, MA. The company is initially focused on harnessing the potential of "cloaked" immune cells for cancer treatment. Clade Therapeutics is led by a world-class team of company builders and scientific innovators with unparalleled expertise in generating stem cell-derived adult T, NK, and B cells. The company is supported by a premier investor syndicate, including Lifesci Venture Partners, Emerson Collective, and Bristol-Myers Squibb. The company was founded by Jim Glasheen, Deepta Bhattacharya, Chris Sturgeon, Gustavo Mostoslavsky, Leandro Vetcher, Chad Cowan, and Chad Cowan has been the CEO since incorporation. | Biotechnology | Director/Board Member | |
Resolution Therapeutics Ltd.
Resolution Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Resolution Therapeutics Ltd. operates as a macrophage cell therapy company. The company was founded on December 14, 2017 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Weill Cornell Medicine | College/University | Corporate Officer/Principal | |
Amphista Therapeutics Ltd.
Amphista Therapeutics Ltd. BiotechnologyHealth Technology Amphista Therapeutics Ltd. is a biopharmaceutical company based in Biocity Glasgow, UK. The British company is focused on creating first-in-class therapeutics that selectively and efficiently degrade and remove disease-causing proteins using targeted protein degradation (TPD). The company's pipeline of novel small molecules is focused on challenging diseases, including cancer. Amphista is a spin-out of Professor Alessio Ciulli's labs at the University of Dundee and is funded by leading life science investors, including Advent Life Sciences, the European Investment Fund, the Scottish Investment Bank, and Biomotiv. The CEO of the company is Nicola Thompson. | Biotechnology | Director/Board Member | |
MINERALYS THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
ACRIVON THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
CANBRIDGE PHARMACEUTICALS INC. | Pharmaceuticals: Major | Director/Board Member | |
DAY ONE BIOPHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
CONNECT BIOPHARMA HOLDINGS LIMITED | Pharmaceuticals: Major | Director/Board Member | |
ITEOS THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Canbridge Pharmaceuticals, Inc. (United States)
Canbridge Pharmaceuticals, Inc. (United States) BiotechnologyHealth Technology Part of CANbridge Pharmaceuticals Inc., Canbridge Pharmaceuticals is a rare disease-focused biopharmaceutical company based in Cambridge, MA. Canbridge Pharmaceuticals, Inc. (United States) was established in 2012 and is committed to researching, developing, and commercializing transformative therapies for rare diseases. | Biotechnology | Director/Board Member | |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Investment Managers | Private Equity Investor |
Statistiche
Distribuzione geografica
Regno Unito | 23 |
Stati Uniti | 20 |
Svizzera | 3 |
Cina | 3 |
Paesi Bassi | 2 |
Settori
Health Technology | 27 |
Finance | 9 |
Consumer Services | 8 |
Commercial Services | 3 |
Health Services | 3 |
Posizioni
Director/Board Member | 67 |
Chairman | 30 |
Corporate Officer/Principal | 21 |
Independent Dir/Board Member | 17 |
Undergraduate Degree | 9 |
Contatti più connessi
Insiders | |
---|---|
Edwin Moses | 35 |
Martin Murphy | 33 |
Derek DiRocco | 17 |
Carsten Boess | 15 |
Iraj Ali | 10 |
Michael Giordano | 9 |
Elisa Petris | 7 |
Karl Peggs | 7 |
Rogier Rooswinkel | 4 |
Dara Henry | 1 |
- Borsa valori
- Insiders
- Liz Elmhirst
- Connessioni Società